BillionToOne Inc

BLLN

Market cap $3.8B

The mean of analysts' price targets for BillionToOne (BLLN) points to a 25.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Although the revenue and EPS for BillionToOne (BLLN) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

MENLO PARK, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today reported its financial results for the first quarter ended March 31, 2026 and raised guidance for full year 2026.

A breakthrough in prenatal care, Unity Confirm enables non-invasive confirmation for high-risk screening results through the capture of intact circulating fetal cells using BillionToOne's Fetal Cell Capture™ Technology MENLO PARK, Calif., May 1, 2026 /PRNewswire/ -- For more than two decades, the ultimate quest for scientists and clinicians studying prenatal genetics was the capture of an intact fetal cell non-invasively so that its fetal DNA could be directly analyzed.

Renowned physician executive and clinician-scientist joins BillionToOne to advance oncology medical strategy MENLO PARK, Calif., April 2, 2026 /PRNewswire/ -- BillionToOne , Inc. (Nasdaq: BLLN), a next-generation molecular diagnostics company focused on making highly accurate testing accessible to all, today announced the appointment of Allen Chen, MD, MBA, FASTRO, FACHE, as Vice President of Medical Affairs and Clinical Development, Oncology.

BillionToOne, Inc. (BLLN) Q4 2025 Earnings Call Transcript

BillionToOne delivers strong growth in molecular diagnostics, achieving profitability and raising 2026 revenue guidance to $430–$445 million. BillionToOne's Q4 sales rose 113% to $96.1 million, driven by prenatal testing; oncology growth was slower sequentially but remains a long-term diversification lever. I view current guidance as conservative, with recent product launches and coverage deals not fully reflected in the outlook, supporting further upside potential.

Although the revenue and EPS for BillionToOne (BLLN) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

MENLO PARK, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today reported its financial results for the fourth quarter and full year ended December 31, 2025 and raised guidance for full year 2026.

MENLO PARK, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that the Company plans to release its financial results for fourth quarter and full year ended December 31, 2025 after the market close on Wednesday, March 4, 2026. BillionToOne will host a conference call to discuss its financial results at 1:30pm Pacific Time / 4:30pm Eastern Time the same day.